切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2021, Vol. 10 ›› Issue (02) : 158 -163. doi: 10.3877/cma.j.issn.2095-3224.2021.02.008

所属专题: 文献

论著

肿瘤间质比在Ⅱ、Ⅲ期结直肠癌患者预后评估中的价值
李腾飞1, 杨彦1, 黄陈1,()   
  1. 1. 233000 蚌埠医学院研究生院;201600 上海交通大学附属第一人民医院胃肠外科
  • 收稿日期:2020-11-16 出版日期:2021-04-25
  • 通信作者: 黄陈
  • 基金资助:
    国家自然科学基金面上项目(82072662,817725276); 上海交通大学医院高峰高原计划(20161425); 上海交通大学医工交叉项目(YG2017MS28); 上海市级医院临床技能与临床创新三年行动计划(SHDC2020CR4022)

Value of tumor stroma ratio in evaluating the prognosis of patients with stage II and III colorectal cancer

Tengfei Li1, Yan Yang1, Chen Huang1,()   

  1. 1. Graduate School of Bengbu Medical College, Bengbu 233000, China; Department of Gastrointestinal Surgery, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 201600, China
  • Received:2020-11-16 Published:2021-04-25
  • Corresponding author: Chen Huang
引用本文:

李腾飞, 杨彦, 黄陈. 肿瘤间质比在Ⅱ、Ⅲ期结直肠癌患者预后评估中的价值[J/OL]. 中华结直肠疾病电子杂志, 2021, 10(02): 158-163.

Tengfei Li, Yan Yang, Chen Huang. Value of tumor stroma ratio in evaluating the prognosis of patients with stage II and III colorectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(02): 158-163.

目的

评估肿瘤间质比(TSR)在Ⅱ、Ⅲ期CRC患者预后评估中的价值。

方法

收集820例接受完全治愈性切除(R0切除)Ⅱ、Ⅲ期结直肠癌(CRC)患者的临床资料,比较低TSR组和高TSR组患者的临床病理特征及生存情况,分析影响患者总生存率的危险因素。

结果

TSR高(TSR>50%)者307例,TSR低(TSR≤50%)者513例。高TSR组CRC患者的5年总体生存率为76.2%(243/307)低于低TSR组CRC患者的5年总体生存率为83.2%(427/513),差异有统计学意义(χ2=7.991,P=0.0047)。多因素分析结果显示,年龄、肿瘤位置、脉管浸润和TSR是影响Ⅱ、Ⅲ期CRC患者总生存率的危险因素(P<0.05)。

结论

TSR是Ⅱ、Ⅲ期CRC患者根治性切除术后远期预后的独立影响因素,可为术后辅助治疗方案的制订提供重要依据。

Objective

To evaluate the prognostic value of tumor stroma ratio (TSR) in stage II and III colorectal cancer patients.

Method

Clinical data of 820 stage II and III colorectal cancer patients who had received complete curative resection (R0 resection) were collected. The clinicopathological characteristics and survival status of patients with low and high TSR were compared, and the risk factors affecting the overall survival rate were analyzed.

Results

There were 307 patients with stroma high (TSR>50%) and 513 patients with stroma low (TSR≤50%). The 5-year overall survival rate of CRC patients with high stromal proportion was 76.2% (243/307), while that of CRC patients with low stromal proportion was 83.2%(427/513), the difference was statistically significant (χ2=7.991, P=0.0047).The results of multivariate analysis showed that age, tumor location, vascular infiltration and TSR were the risk factors affecting the overall survival rate of patients with stage II and III colorectal cancer (P<0.05).

Conclusion

TSR is an independent factor for the long-term prognosis of patients with stage II and III colorectal cancer after radical resection, which can provide an important basis for the formulation of postoperative adjuvant therapy.

图1 从WSI图中导出3张最具有侵袭性的区域,病理学家行视觉评估TSR
表1 Ⅱ、Ⅲ期CRC患者TSR与临床病理相关因素分析[例(%)]
图2 TSR高和TSR低Ⅱ、Ⅲ期CRC患者总体生存率比较
表2 Ⅱ、Ⅲ期CRC患者总体生存率影响因素的单因素COX回归分析
表3 Ⅱ、Ⅲ期CRC患者总体生存率影响因素的多因素COX回归分析
1
Brody H. Colorectal cancer[J]. Nature, 2015, 521(7551): S1.
2
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
3
傅中懋, 黄陈. "偏左,朝右":基于原发部位结肠癌发生机制研究进展及临床治疗决策思辨[J/CD].中华结直肠疾病电子杂志, 2019, 8(6): 546-552.
4
吴涵, 余志龙, 黄陈. 人工智能技术在结直肠癌中的应用与展望[J/CD]. 中华结直肠疾病电子杂志, 2019, 8(2): 115-119.
5
Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage[J]. Cell Oncol, 2007, 29(5): 387-398.
6
West NP, Dattani M, McShane P, et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients[J]. Br J Cancer, 2010, 102(10): 1519-1523.
7
De Kruijf EM, van Nes JG, van de Velde CJ, et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients[J]. Breast Cancer Res Treat, 2011, 125(3): 687-696.
8
Aurello P, Berardi G, Giulitti D, et al. Tumor-Stroma Ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients[J]. Surgeon, 2017, 15(6): 329-335.
9
Zunder S, van der Wilk P, Gelderblom H, et al. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial[J]. Cell Oncol (Dordr), 2019, 42(5): 717-725.
10
Huijbers A, Tollenaar RA, Pelt GW, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and Ⅲ colon cancer patients: validation in the VICTOR trial [J]. Ann Oncol, 2013, 24(1): 179485.
11
Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study[J]. Ann Oncol, 2017, 28(5): 1023-1031.
12
Mesker WE, Junggeburt JM, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival comnared to lymph node status and tumor stage[J]. Cell Oncol, 2007, 29(5): 387-398.
13
李腾飞, 黄陈. 肿瘤间质成分在结直肠癌中的研究现状及进展[J/CD]. 中华结直肠疾病电子杂志, 2020, 9(5): 447-452.
14
Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses[J]. J Clin Oncol, 2011, 29(28): 3768-3774.

URL    
15
Labianca R, Nordlinger B, Beretta GD, et al. ESMO guidelines working group. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24(Suppl 6): vi64-72.
16
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018; 16(4): 359-369.
17
Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(10): 1291-1305.
18
Zunder SM, van Pelt GW, Gelderblom HJ, et al. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer[J]. Br J Cancer, 2018, 119(2): 164-169.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[10] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[11] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[12] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[13] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要